Author

Palak Sharma

Intellia Therapeutics (United States)ORCID 0000-0001-8870-9097Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Bioengineering· 1 Synthetic Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 2 Assay:CRISPR screen· 1 Approach:deep learning· 1 Research Focus:gene regulatory network inference· 1 Organism:human· 1 Organism:mouse· 1

Frequent Co-Authors

Aaron ProdeusiD· 2 shared Allie Luther· 2 shared Birgit C. SchultesiD· 2 shared Dai LiuiD· 2 shared Ian C. Miller· 2 shared Ishina BalwaniiD· 2 shared Ivy Dutta· 2 shared Qingzhan Zhang· 2 shared

Activity by Year

2025-2026 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersSynthetic Biology

Aaron ProdeusORCID

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Synthetic BiologybioRxivPreprintJul 28, 2026

Engineering antigen-driven co-stimulation and T helper cell activity into TCR-T cells with CD8-41BB fusion receptors enhances anti-tumor activity

Ivy Dutta, Justin Oh, Liz Cam…·Aaron Prodeus

This paper enhances TCR-T cell anti-tumor activity by engineering CD8-41BB fusion receptors, improving CD4+ and CD8+ T cell functions and tumor regression in mouse models.

DOI 10.64898/2026.07.27.739613

mouseexperimental assay

𝕏 PostBluesky

BioengineeringCytotherapyPeer-reviewedOct 11, 2025

A differentiated and durable allogeneic strategy applicable to cell therapies

Utsav Jetley, Ishina Balwani, Palak Sharma…·Yong Zhang

This paper develops an allogeneic T cell therapy strategy using gene editing to reduce immune rejection and enable off-the-shelf use, showing comparable function to autologous cells.

5 citations

humanCRISPR screen

𝕏 PostBluesky